A History of the Molecular Initiating Event

被引：43

作者：

Allen, Timothy E. H. ^{[1
]}

Goodman, Jonathan M. ^{[1
]}

Gutsell, Steve ^{[2
]}

Russell, Paul J. ^{[2
]}

机构：

[1] Univ Cambridge, Dept Chem, Ctr Mol Informat, Lensfield Rd, Cambridge CB2 1EW, England

[2] Unilever Safety & Environm Assurance Ctr, Colworth Sci Pk, Sharnbrook MK44 1LQ, Beds, England

来源：

CHEMICAL RESEARCH IN TOXICOLOGY | 2016年 / 29卷 / 12期

关键词：

ADVERSE OUTCOME PATHWAYS; HEALTH-RISK ASSESSMENT; IN-SILICO PROFILER; SKIN SENSITIZATION; CONCEPTUAL-FRAMEWORK; END-POINTS; TOXICITY; TOXICOLOGY; CHEMICALS; MODE;

D O I：

10.1021/acs.chemrestox.6b00341

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The adverse outcome pathway (AOP) framework provides an alternative to traditional in vivo experiments for the risk assessment of chemicals. AOPs consist of a number of key events (KEs) linked by key event relationships across a range of biological organization backed by scientific evidence. The first ICE in the pathway is the molecular initiating event (MIE) the initial chemical trigger that starts an AOP. Over the past 3 years the AOP conceptual framework has gained a large amount of momentum in toxicology as an alternative to animal methods, and so the MIE has come into the spotlight. What is an MIE? How can MIEs be measured or predicted? What research is currently contributing to our understanding of MIEs? In this Perspective we outline answers to these key questions.

引用

页码：2060 / 2070

页数：11

共 61 条

[1] Toxicology and genetic toxicology in the new era of "toxicogenomics": impact of "-omics" technologies [J].

Aardema, MJ ;

MacGregor, JT .

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2002, 499 (01) :13-25

[2] Defining Molecular Initiating Events in the Adverse Outcome Pathway Framework for Risk Assessment [J].

Allen, Timothy E. H. ;

Goodman, Jonathan M. ;

Gutsell, Steve ;

Russell, Paul J. .

CHEMICAL RESEARCH IN TOXICOLOGY, 2014, 27 (12) :2100-2112

[3] PHYSIOLOGICALLY BASED PHARMACOKINETICS AND THE RISK ASSESSMENT PROCESS FOR METHYLENE-CHLORIDE [J].

ANDERSEN, ME ;

CLEWELL, HJ ;

GARGAS, ML ;

SMITH, FA ;

REITZ, RH .

TOXICOLOGY AND APPLIED PHARMACOLOGY, 1987, 87 (02) :185-205

[4] Probe Molecule (PrM) Approach in Adverse Outcome Pathway (AOP) Based High-Throughput Screening (HTS): In Vivo Discovery for Developing in Vitro Target Methods [J].

Angrish, Michelle M. ;

Madden, Michael C. ;

Pleil, Joachim D. .

CHEMICAL RESEARCH IN TOXICOLOGY, 2015, 28 (04) :551-559

[5] ADVERSE OUTCOME PATHWAYS: A CONCEPTUAL FRAMEWORK TO SUPPORT ECOTOXICOLOGY RESEARCH AND RISK ASSESSMENT [J].

Ankley, Gerald T. ;

Bennett, Richard S. ;

Erickson, Russell J. ;

Hoff, Dale J. ;

Hornung, Michael W. ;

Johnson, Rodney D. ;

Mount, David R. ;

Nichols, John W. ;

Russom, Christine L. ;

Schmieder, Patricia K. ;

Serrrano, Jose A. ;

Tietge, Joseph E. ;

Villeneuve, Daniel L. .

ENVIRONMENTAL TOXICOLOGY AND CHEMISTRY, 2010, 29 (03) :730-741

[6]

[Anonymous], OECD SER TEST ASS

[7]

[Anonymous], 2012, Proposal for a Template and Guidance on Developing and Assessing the Completeness of Adverse Outcome Pathways

[8] Mechanistic applicability domains for nonanimal-based prediction of toxicological end points: General principles and application to reactive toxicity [J].

Aptula, Aynur O. ;

Roberts, David W. .

CHEMICAL RESEARCH IN TOXICOLOGY, 2006, 19 (08) :1097-1105

[9] MODE OF ACTION AND THE ASSESSMENT OF CHEMICAL HAZARDS IN THE PRESENCE OF LIMITED DATA - USE OF STRUCTURE-ACTIVITY-RELATIONSHIPS (SAR) UNDER TSCA, SECTION-5 [J].

AUER, CM ;

NABHOLZ, JV ;

BAETCKE, KP .

ENVIRONMENTAL HEALTH PERSPECTIVES, 1990, 87 :183-197

[10] Increasing Scientific Confidence in Adverse Outcome Pathways: Application of Tailored Bradford-Hill Considerations for Evaluating Weight of Evidence [J].

Becker, Richard A. ;

Ankley, Gerald T. ;

Edwards, Stephen W. ;

Kennedy, Sean W. ;

Linkov, Igor ;

Meek, Bette ;

Sachana, Magdalini ;

Segner, Helmut ;

Van der Burg, Bart ;

Villeneuve, Daniel L. ;

Watanabe, Haruna ;

Barton-Maclaren, Tara S. .

REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2015, 72 (03) :514-537

← 1 2 3 4 5 6 7 →